BRPI0313613B1 - variantes do principal alérgeno phl p 1 de capim-timóteo, suas formas de enovelamento lm e hm, seus usos e seus processos de preparação e de purificação, molécula de dna, vetor de expressão de dna recombinante e seu uso, e composições farmacêuticas - Google Patents
variantes do principal alérgeno phl p 1 de capim-timóteo, suas formas de enovelamento lm e hm, seus usos e seus processos de preparação e de purificação, molécula de dna, vetor de expressão de dna recombinante e seu uso, e composições farmacêuticas Download PDFInfo
- Publication number
- BRPI0313613B1 BRPI0313613B1 BRPI0313613A BR0313613A BRPI0313613B1 BR PI0313613 B1 BRPI0313613 B1 BR PI0313613B1 BR PI0313613 A BRPI0313613 A BR PI0313613A BR 0313613 A BR0313613 A BR 0313613A BR PI0313613 B1 BRPI0313613 B1 BR PI0313613B1
- Authority
- BR
- Brazil
- Prior art keywords
- allergen
- variant
- rphl
- phl
- preparation
- Prior art date
Links
- 239000013566 allergen Substances 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 238000000746 purification Methods 0.000 title claims abstract description 24
- 241000746983 Phleum pratense Species 0.000 title claims abstract description 14
- 108020004414 DNA Proteins 0.000 title claims description 14
- 239000013604 expression vector Substances 0.000 title claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- 102000053602 DNA Human genes 0.000 title claims description 5
- 108020004511 Recombinant DNA Proteins 0.000 title claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 230000007815 allergy Effects 0.000 claims description 25
- 208000026935 allergic disease Diseases 0.000 claims description 20
- 239000013522 chelant Substances 0.000 claims description 20
- 238000001042 affinity chromatography Methods 0.000 claims description 19
- 238000002523 gelfiltration Methods 0.000 claims description 18
- 238000004925 denaturation Methods 0.000 claims description 14
- 230000036425 denaturation Effects 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 210000003000 inclusion body Anatomy 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 238000010790 dilution Methods 0.000 claims description 9
- 239000012895 dilution Substances 0.000 claims description 9
- 238000004153 renaturation Methods 0.000 claims description 9
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 7
- 238000002955 isolation Methods 0.000 claims description 7
- 238000010828 elution Methods 0.000 claims description 5
- 238000009169 immunotherapy Methods 0.000 claims description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 4
- 230000001024 immunotherapeutic effect Effects 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 244000025254 Cannabis sativa Species 0.000 claims description 3
- 235000019750 Crude protein Nutrition 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 229910021645 metal ion Inorganic materials 0.000 claims description 3
- 230000002018 overexpression Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000002255 vaccination Methods 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 241001148683 Zostera marina Species 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 210000001541 thymus gland Anatomy 0.000 claims 1
- 230000009465 prokaryotic expression Effects 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 20
- 229960004784 allergens Drugs 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 230000004927 fusion Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000009739 binding Methods 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 230000009257 reactivity Effects 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 239000012505 Superdex™ Substances 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000010188 recombinant method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 238000011238 DNA vaccination Methods 0.000 description 3
- 229940074608 allergen extract Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000002797 proteolythic effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 108010076818 TEV protease Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002009 allergenic effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 229940046528 grass pollen Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 241000254032 Acrididae Species 0.000 description 1
- 239000010267 Allergoid Substances 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 240000004296 Lolium perenne Species 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000013572 airborne allergen Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 230000000468 autoproteolytic effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000013574 grass pollen allergen Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- -1 imidazole compound Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 201000004338 pollen allergy Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000007281 self degradation Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Botany (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02018157 | 2002-08-19 | ||
| PCT/EP2003/008471 WO2004022588A1 (de) | 2002-08-19 | 2003-07-31 | Varianten des majorallergens phl p 1 aus lieschgras |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR0313613A BR0313613A (pt) | 2005-06-21 |
| BRPI0313613B1 true BRPI0313613B1 (pt) | 2016-06-07 |
Family
ID=31970262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0313613A BRPI0313613B1 (pt) | 2002-08-19 | 2003-07-31 | variantes do principal alérgeno phl p 1 de capim-timóteo, suas formas de enovelamento lm e hm, seus usos e seus processos de preparação e de purificação, molécula de dna, vetor de expressão de dna recombinante e seu uso, e composições farmacêuticas |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US7731970B2 (https=) |
| EP (1) | EP1532169B1 (https=) |
| JP (2) | JP4668616B2 (https=) |
| CN (1) | CN100509844C (https=) |
| AU (1) | AU2003251674B2 (https=) |
| BR (1) | BRPI0313613B1 (https=) |
| CA (1) | CA2495825C (https=) |
| ES (1) | ES2400181T3 (https=) |
| PL (1) | PL212891B1 (https=) |
| PT (1) | PT1532169E (https=) |
| RU (1) | RU2323942C2 (https=) |
| WO (1) | WO2004022588A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2323942C2 (ru) * | 2002-08-19 | 2008-05-10 | Мерк Патент Гмбх | ВАРИАНТЫ ОСНОВНОГО АЛЛЕРГЕНА Phl p 1 ИЗ ТИМОФЕЕВКИ ЛУГОВОЙ |
| DE102004035337A1 (de) * | 2004-07-21 | 2006-03-16 | Merck Patent Gmbh | Varianten der Gruppe 1-Allergene aus Poaceae mit reduzierter Allergenität und erhaltener T-Zellreaktivität |
| MX2014009285A (es) * | 2012-02-07 | 2015-02-04 | Jolla Inst Allergy Immunolog | Alergenos del fleo de los prados y metodos y usos para la modulacion de respuesta inmune. |
| JP6102442B2 (ja) * | 2013-04-04 | 2017-03-29 | 日産自動車株式会社 | リチウムイオン二次電池 |
| CN113825518A (zh) | 2019-01-17 | 2021-12-21 | 莱蒂生物制药公司 | 纯化过敏原提取物的方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05509230A (ja) * | 1990-08-17 | 1993-12-22 | ザ・ユニバーシテイ・オブ・メルボルン | ライグラスの花粉のアレルゲン |
| IL115177A0 (en) * | 1994-09-16 | 1995-12-31 | Immunomedics Inc | Phosphorus-32 labeling of antibodies for cancer therapy |
| US6281332B1 (en) * | 1994-12-02 | 2001-08-28 | The Johns Hopkins University School Of Medicine | Hedgehog-derived polypeptides |
| CA2267106A1 (en) * | 1996-10-07 | 1998-07-16 | The Johns Hopkins University School Of Medicine | Novel hedgehog-derived polypeptides |
| GB2348808B (en) * | 1998-01-09 | 2003-03-19 | Circassia Ltd | Methods and compositions for desensitisation |
| DE19918682A1 (de) * | 1999-04-23 | 2000-10-26 | Merck Patent Gmbh | DNA-Sequenz und rekombinante Herstellung eines Graminaen-Allergens |
| US20070011783A1 (en) * | 1999-05-06 | 2007-01-11 | Jingdong Liu | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| US20100293669A2 (en) * | 1999-05-06 | 2010-11-18 | Jingdong Liu | Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement |
| IT1318692B1 (it) | 2000-09-12 | 2003-08-27 | Consiglio Nazionale Ricerche | Varianti di proteine allergeniche di phleum pratense. |
| AU2002256276A1 (en) * | 2001-04-19 | 2002-11-05 | Penn State Research Foundation | Novel expansin polynucleotides, related polypeptides and methods of use |
| RU2323942C2 (ru) * | 2002-08-19 | 2008-05-10 | Мерк Патент Гмбх | ВАРИАНТЫ ОСНОВНОГО АЛЛЕРГЕНА Phl p 1 ИЗ ТИМОФЕЕВКИ ЛУГОВОЙ |
-
2003
- 2003-07-31 RU RU2005107782/13A patent/RU2323942C2/ru not_active IP Right Cessation
- 2003-07-31 ES ES03793667T patent/ES2400181T3/es not_active Expired - Lifetime
- 2003-07-31 PT PT37936671T patent/PT1532169E/pt unknown
- 2003-07-31 WO PCT/EP2003/008471 patent/WO2004022588A1/de not_active Ceased
- 2003-07-31 JP JP2004533298A patent/JP4668616B2/ja not_active Expired - Fee Related
- 2003-07-31 CN CNB038198231A patent/CN100509844C/zh not_active Expired - Fee Related
- 2003-07-31 CA CA2495825A patent/CA2495825C/en not_active Expired - Lifetime
- 2003-07-31 US US10/525,000 patent/US7731970B2/en not_active Expired - Fee Related
- 2003-07-31 AU AU2003251674A patent/AU2003251674B2/en not_active Ceased
- 2003-07-31 EP EP03793667A patent/EP1532169B1/de not_active Expired - Lifetime
- 2003-07-31 PL PL373069A patent/PL212891B1/pl unknown
- 2003-07-31 BR BRPI0313613A patent/BRPI0313613B1/pt not_active IP Right Cessation
-
2010
- 2010-03-22 US US12/728,745 patent/US9453058B2/en not_active Expired - Fee Related
- 2010-11-08 JP JP2010249581A patent/JP5868587B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2495825A1 (en) | 2004-03-18 |
| AU2003251674B2 (en) | 2009-09-03 |
| RU2323942C2 (ru) | 2008-05-10 |
| JP5868587B2 (ja) | 2016-02-24 |
| US9453058B2 (en) | 2016-09-27 |
| ES2400181T3 (es) | 2013-04-08 |
| JP4668616B2 (ja) | 2011-04-13 |
| PL373069A1 (en) | 2005-08-08 |
| PT1532169E (pt) | 2013-03-18 |
| CN100509844C (zh) | 2009-07-08 |
| US20060251682A1 (en) | 2006-11-09 |
| JP2006516382A (ja) | 2006-07-06 |
| CN1675240A (zh) | 2005-09-28 |
| WO2004022588A1 (de) | 2004-03-18 |
| RU2005107782A (ru) | 2005-11-20 |
| EP1532169A1 (de) | 2005-05-25 |
| CA2495825C (en) | 2015-03-17 |
| US20120263741A1 (en) | 2012-10-18 |
| AU2003251674A1 (en) | 2004-03-29 |
| JP2011097940A (ja) | 2011-05-19 |
| EP1532169B1 (de) | 2012-12-19 |
| PL212891B1 (pl) | 2012-12-31 |
| US7731970B2 (en) | 2010-06-08 |
| BR0313613A (pt) | 2005-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3049353C (en) | Mycobacteria tuberculosis chaperonin 60.1 peptides and uses thereof | |
| EP3206713A2 (en) | Interleukin-15 compositions and uses thereof | |
| US9453058B2 (en) | Variants of the major allergen Phl P 1 from timothy grass | |
| HUP0200958A2 (en) | Method for down-regulating il5 activity | |
| US9522938B2 (en) | Phl p 5a derivatives having reduced allergeneity and retained T-cell reactivity | |
| JP2005518194A (ja) | 乱交雑ｔ細胞エピトープ挿入物を有するマルチマータンパク質の免疫原性擬態物 | |
| US9309297B2 (en) | DNA sequence, and recombinant preparation of group 4 major allergens from cereals | |
| JP4343702B2 (ja) | 低アレルギー性シラカバ花粉主要アレルゲンｒＢｅｔｖ１の製造方法 | |
| RU2409589C2 (ru) | ВАРИАНТ АЛЛЕРГЕНА ГРУППЫ I ИЗ Роасеае, ХАРАКТЕРИЗУЮЩИЙСЯ СНИЖЕННОЙ АЛЛЕРГЕННОСТЬЮ И СОХРАНЕННОЙ Т-КЛЕТОЧНОЙ РЕАКТИВНОСТЬЮ (ВАРИАНТЫ), КОДИРУЮЩАЯ ЕГО МОЛЕКУЛА ДНК И ЕГО ПРИМЕНЕНИЕ | |
| CN102791289B (zh) | 因脯氨酸残基突变而具有降低变应原性的真禾本科第5组变应原的变体 | |
| EP2079758B1 (en) | Method for the purification of dnak | |
| AU2012205288A1 (en) | DNA-sequence and recombinant production of group 4 major allergens from cereals | |
| WO2000078804A1 (fr) | Proteines regulatrices de la reponse immunitaire |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
| B07E | Notice of approval relating to section 229 industrial property law |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06A | Notification to applicant to reply to the report for non-patentability or inadequacy of the application according art. 36 industrial patent law | ||
| B06A | Notification to applicant to reply to the report for non-patentability or inadequacy of the application according art. 36 industrial patent law | ||
| B09A | Decision: intention to grant | ||
| B16A | Patent or certificate of addition of invention granted |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/06/2016, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 15A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2473 DE 29-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |